Abir Therapeutics Ltd. acquired 6.21% stake in Protalix BioTherapeutics, Inc. for $3.5 million.
January 25, 2017
Share
Abir Therapeutics Ltd. acquired 6.21% stake in Protalix BioTherapeutics, Inc. (AMEX:PLX) for $3.5 million on January 26, 2017. Abir Therapeutics acquired 6.2 million shares at a price of $0.57 per share.
Abir Therapeutics Ltd. completed the acquisition of 6.21% stake in Protalix BioTherapeutics, Inc. (AMEX:PLX) on January 26, 2017.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
PROTALIX BIOTHERAPEUTICS, INC. 
